LSTA

Strip away the deal and Lisata is a clinical-stage cash-burner with no business to value: FY2025 revenue was $170K (down 83% YoY) — essentially milestone dust, not commercial sales — against a -$16.6M net loss and -$15.9M operating cash flow. With $16.0M of cash (~$1.77/share) and burn of ~$16M/year, standalone runway is roughly one year, and management concedes it is boxed in — the ATM sits under the Baby Shelf Limitation (only ~$9.9M sellable, and it raised just $0.78M in 2025), so any raise would be steeply dilutive. The lead asset certepetide remains Phase 2 with no approvals, and the January 2026 mutual termination of the Qilu license and collaboration agreement stripped away its partnered China path. On its own numbers and pipeline, this is an 'avoid.'

What changes the picture entirely is the March 6, 2026 Merger Agreement: Kuva Labs will commence a tender offer at $5.00/share cash plus one non-tradeable CVR worth $1.00 if a milestone is met — up to $6.00 versus the $3.33 price. That is a ~50% spread to the cash floor alone, extraordinarily wide for a signed all-cash tender that Kuva 'will be required to close so long as' a majority of shares are tendered. A spread that wide is the market's verdict, not a gift: it implies roughly coin-flip odds the deal actually closes, likely reflecting doubts about privately-held Kuva's financing and the customary conditions the filing flags as unresolved ('we cannot predict whether and when the conditions to closing will be satisfied').